m6A-centered Crosstalk Information

Mechanism of Crosstalk between m6A Modification and Epigenetic Regulation
Crosstalk ID
M6ACROT05222
 [1]
Non-coding RNA CircASPH IGF2BP2  lncRNA       miRNA   circRNA Direct Enhancement m6A modification STING1 STING1 IGF2BP2 : m6A sites
m6A Modification:
m6A Regulator Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) READER
 Regulator Info 
m6A Target Stimulator of interferon genes protein (STING1)
 Targert Gene 
Epigenetic Regulation that have Cross-talk with This m6A Modification:
Epigenetic Regulation Type Non-coding RNA (ncRNA)
Epigenetic Regulator Circ_ASPH circRNA View Details
Regulated Target Insulin like growth factor 2 mRNA binding protein 2 (IGF2BP2) View Details
Crosstalk Relationship ncRNA  →  m6A Enhancement
Crosstalk Mechanism ncRNAs directly impacts m6A modification through recruiting m6A regulator
Crosstalk Summary Circ_ASPH interacted with insulin-like growth factor 2 mRNA binding protein 2 (IGF2BP2) to stabilize IGF2BP2 protein, therefore enhancing the stability of m6A-modified Stimulator of interferon genes protein (STING1) mRNA.
Responsed Disease Colorectal cancer ICD-11: 2B91
 Disease Info 
In-vitro Model
 FHC Normal Homo sapiens CVCL_3688
LoVo Colon adenocarcinoma Homo sapiens CVCL_0399
HT-29 Colon adenocarcinoma Homo sapiens CVCL_0320
SW480 Colon adenocarcinoma Homo sapiens CVCL_0546
SW620 Colon adenocarcinoma Homo sapiens CVCL_0547
THP-1 Childhood acute monocytic leukemia Homo sapiens CVCL_0006
In-vivo Model Briefly, 5 × 105 LoVo cells stably transfected with sh-NC or sh-circASPH#1 were subcutaneously injected into the right back of each mice in 2 groups. To evaluate the effect of STING-overexpressed macrophages on tumor growth, LoVo cells stably transfected with sh-NC or sh-circASPH#1 were separately cocultured with STING-overexpressed macrophages.
Full List of Potential Compound(s) Related to This m6A-centered Crosstalk
Stimulator of interferon genes protein (STING1) 17 Compound(s) Regulating the Target Click to Show/Hide the Full List
 Compound Name ADU-S100 Phase 2 [2]
Synonyms
MIW815; IZJJFUQKKZFVLH-LTKSHMRXSA-N; 1638241-89-0; AKOS027321070; HY-12885
    Click to Show/Hide
MOA Activator
External Link
CID: 135390762
TTD: D0N6VS
 Compound Name ADU- S100 Phase 2 [3]
MOA Agonist
External Link
TTD: DCIX20
 Compound Name MK-1454 Phase 2 [4]
MOA Agonist
External Link
TTD: DQ4OU8
 Compound Name IMSA101 Phase 1/2 [5]
MOA Agonist
External Link
TTD: DC37YW
 Compound Name BMS-986301 Phase 1 [6]
MOA Agonist
External Link
TTD: D2KOX5
 Compound Name MK-2118 Phase 1 [7]
MOA Agonist
External Link
TTD: D4JU8H
 Compound Name XMT-2056 Phase 1 [8]
MOA Agonist
External Link
TTD: D7AT3H
 Compound Name TAK-500 Phase 1 [9]
MOA Agonist
External Link
TTD: D9ICV2
 Compound Name SB 11285 Phase 1 [10]
MOA Agonist
External Link
TTD: DA79HM
 Compound Name E7766 Phase 1 [11]
MOA Agonist
External Link
TTD: DO7D1L
 Compound Name GSK3745417 Phase 1 [12]
MOA Agonist
External Link
TTD: DQ6J0W
 Compound Name A296 Phase 1 [13]
MOA Agonist
External Link
TTD: DTV17S
 Compound Name TAK-676 Phase 1 [14]
MOA Agonist
External Link
TTD: DTYQ45
 Compound Name SNX281 Phase 1 [15]
MOA Inhibitor
External Link
TTD: DUA7N4
 Compound Name SYNB1891 Phase 1 [16]
MOA Agonist
External Link
TTD: DUR0F6
 Compound Name C-178 Investigative [17]
Synonyms
329198-87-0; STING inhibitor C-178; N-(dibenzo[b,d]furan-3-yl)-5-nitrofuran-2-carboxamide; N-dibenzofuran-3-yl-5-nitrofuran-2-carboxamide; Oprea1_355995; Oprea1_671722; 5-Nitro-furan-2-carboxylic acid dibenzofuran-3-ylamide; SCHEMBL21065360; BCP31292; ZINC4838645; s6667; AKOS000544527; MCULE-6315822200; BS-17017; C 178;C178;STING inhibitor C-178; HY-123963; CS-0087693; ST51004028; N-benzo[3,4-b]benzo[d]furan-3-yl(5-nitro(2-furyl))carboxamide
    Click to Show/Hide
MOA Agonist
External Link
CID: 2866412
TTD: D7CI5F
 Compound Name C-176 Investigative [18]
Synonyms
314054-00-7; N-(4-iodophenyl)-5-nitrofuran-2-carboxamide; C-176 STING inhibitor; STING inhibitor C-176; STING Inhibitor 1; Cambridge id 5344639; Oprea1_000586; Oprea1_014551; 5-Nitro-furan-2-carboxylic acid (4-iodo-phenyl)-amide; CHEMBL3593839; SCHEMBL13219564; ZINC830011; BCP30174; EX-A2974; s6575; STK016322; AKOS000670518; MCULE-4963641555; BS-16912; HY-112906; AK00792625; CS-0067918; ST50232559; C176; C 176; AB00081654-01; N-(4-iodophenyl)(5-nitro(2-furyl))carboxamide; SR-01000406953; SR-01000406953-1
    Click to Show/Hide
MOA Agonist
External Link
CID: 1103958
TTD: DP2F6W
2B91: Colorectal cancer 25 Compound(s) Regulating the Disease Click to Show/Hide the Full List
 Compound Name Retifanlimab Approved [19]
Synonyms
INCMGA0012; Retifanlimab
    Click to Show/Hide
External Link
TTD: D0PG5O
 Compound Name Aflibercept Approved [20]
Synonyms
Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye
    Click to Show/Hide
External Link
TTD: D0C9ET
 Compound Name Regorafenib Approved [21]
Synonyms
755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]
    Click to Show/Hide
External Link
CID: 11167602
TTD: D09GDD
DrugBank: DB08896
 Compound Name Bevacizumab Approved [2]
Synonyms
Bevacizumab (ophthalmic slow-release tissue tablet)
    Click to Show/Hide
External Link
TTD: D04KBL
 Compound Name SYM-004 Phase 3 [2]
Synonyms
Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen
    Click to Show/Hide
External Link
TTD: D0CR8H
 Compound Name Bevacizumab + Erlotinib Phase 3 [22]
External Link
TTD: D09BKY
 Compound Name CPI-613 Phase 3 [2]
Synonyms
95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874
    Click to Show/Hide
External Link
CID: 24770514
TTD: D07NVI
DrugBank: DB12109
 Compound Name Bevacizumab Approved [20]
External Link
TTD: D0FX3U
 Compound Name AlloStim Phase 2/3 [23]
Synonyms
AlloStim (TN)
    Click to Show/Hide
External Link
TTD: D0B3CC
 Compound Name Sibrotuzumab Phase 2 [24]
External Link
TTD: DVX3H0
 Compound Name CV301 Phase 2 [25]
External Link
TTD: D9LT5G
 Compound Name Efatutazone Phase 2 [26]
Synonyms
Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione
    Click to Show/Hide
External Link
CID: 9832447
TTD: D0Y8NZ
DrugBank: DB11894
 Compound Name LOR-2040 Phase 2 [27]
External Link
TTD: D0I7NG
 Compound Name RG7221 Phase 2 [28]
External Link
TTD: D06FTM
 Compound Name PEG-SN38 Phase 2 [29]
Synonyms
EZN-2208
    Click to Show/Hide
External Link
CID: 59443782
TTD: D05UFP
 Compound Name MEGF0444A Phase 2 [30]
External Link
TTD: D01LES
 Compound Name Encapsulated cell therapy Phase 1/2 [31]
External Link
TTD: D0XY8C
 Compound Name AB928 Phase 1/2 [32]
External Link
CID: 135242184
TTD: D04UBI
 Compound Name MGD007 Phase 1 [28]
External Link
TTD: D00PEN
 Compound Name BNC-101 Phase 1 [33]
External Link
TTD: DD6AZ5
 Compound Name Navicixizumab Phase 1 [2]
External Link
TTD: D00IVN
 Compound Name RG7160 Discontinued in Phase 2 [34]
External Link
TTD: D0E2CQ
 Compound Name Nimesulide Terminated [35]
Synonyms
51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin
    Click to Show/Hide
External Link
CID: 4495
TTD: D0C0JT
DrugBank: DB04743
 Compound Name Saracatinib Phase 2 [36]
External Link
CID: 10302451
TTD: D05YTN
DrugBank: DB11805
 Compound Name G3139 + Irinotecan Investigative [37]
External Link
CID: 91865905
TTD: D05IAN
References
Ref 1 CircASPH Enhances Exosomal STING to Facilitate M2 Macrophage Polarization in Colorectal Cancer. Inflamm Bowel Dis. 2023 Dec 5;29(12):1941-1956. doi: 10.1093/ibd/izad113.
Ref 2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
Ref 3 Magnitude of Therapeutic STING Activation Determines CD8(+) T Cell-Mediated Anti-tumor Immunity. Cell Rep. 2018 Dec 11;25(11):3074-3085.e5. doi: 10.1016/j.celrep.2018.11.047.
Ref 4 National Cancer Institute Drug Dictionary (drug name MK1454).
Ref 5 Clinical pipeline report, company report or official report of ImmuneSensor Therapeutics.
Ref 6 Challenges and Opportunities in the Clinical Development of STING Agonists for Cancer Immunotherapy. J Clin Med. 2020 Oct 16;9(10):3323. doi: 10.3390/jcm9103323.
Ref 7 National Cancer Institute Drug Dictionary (drug name ML2118).
Ref 8 Clinical pipeline report, company report or official report of GlaxoSmithKline
Ref 9 ClinicalTrials.gov (NCT05070247) An Open-label, Dose Escalation and Expansion, Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of TAK-500, a Novel Stimulator of Interferon Genes Agonist, as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Select Locally Advanced or Metastatic Solid Tumors. U.S.National Institutes of Health.
Ref 10 Clinical pipeline report, company report or official report of F-star Therapeutics.
Ref 11 E7766, a Macrocycle-Bridged Stimulator of Interferon Genes (STING) Agonist with Potent Pan-Genotypic Activity. ChemMedChem. 2021 Jun 7;16(11):1740-1743. doi: 10.1002/cmdc.202100068. Epub 2021 Feb 25.
Ref 12 National Cancer Institute Drug Dictionary (drug name GSK3745417).
Ref 13 Clinical pipeline report, company report or official report of Klus Pharma
Ref 14 National Cancer Institute Drug Dictionary (drug name TAK676).
Ref 15 Clinical pipeline report, company report or official report of Silicon Therapeutics.
Ref 16 Immunotherapy with engineered bacteria by targeting the STING pathway for anti-tumor immunity. Nat Commun. 2020 Jun 1;11(1):2739. doi: 10.1038/s41467-020-16602-0.
Ref 17 Targeting STING with covalent small-molecule inhibitors. Nature. 2018 Jul;559(7713):269-273. doi: 10.1038/s41586-018-0287-8. Epub 2018 Jul 4.
Ref 18 Stimulator of IFN genes mediates neuroinflammatory injury by suppressing AMPK signal in experimental subarachnoid hemorrhage. J Neuroinflammation. 2020 May 25;17(1):165. doi: 10.1186/s12974-020-01830-4.
Ref 19 Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730.
Ref 20 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
Ref 21 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5891).
Ref 22 ClinicalTrials.gov (NCT00130728) A Study to Evaluate the Efficacy of Bevacizumab in Combination With Tarceva for Advanced Non-Small Cell Lung Cancer
Ref 23 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
Ref 24 ClinicalTrials.gov (NCT02198274) Intravenous BIBH 1 in Patients With Metastatic Colorectal Cancer. U.S. National Institutes of Health.
Ref 25 ClinicalTrials.gov (NCT03547999) A Trial of Perioperative CV301 Vaccination in Combination With Nivolumab and Systemic Chemotherapy for Metastatic CRC. U.S. National Institutes of Health.
Ref 26 ClinicalTrials.gov (NCT02152137) Efatutazone With Paclitaxel Versus Paclitaxel Alone in Treating Patients With Advanced Anaplastic Thyroid Cancer. U.S. National Institutes of Health.
Ref 27 ClinicalTrials.gov (NCT00087165) GTI-2040, Docetaxel, and Prednisone in Treating Patients With Prostate Cancer. U.S. National Institutes of Health.
Ref 28 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
Ref 29 ClinicalTrials.gov (NCT01036113) A Phase 2 Study of EZN-2208 in Patients With Metastatic Breast Cancer. U.S. National Institutes of Health.
Ref 30 ClinicalTrials.gov (NCT00909740) A Study of the Safety and Pharmacokinetics of MEGF0444A Administered to Patients With Advanced Solid Tumors. U.S. National Institutes of Health.
Ref 31 VC-01's Path to the Clinic. Viacyte. 2015.
Ref 32 ClinicalTrials.gov (NCT04660812) An Open Label Study Evaluating the Efficacy and Safety of AB928 Based Treatment Combinations in Patients With Metastatic Colorectal Cancer.. U.S. National Institutes of Health.
Ref 33 ClinicalTrials.gov (NCT02726334) A Phase I, Dose Escalation Study of BNC101 in Patients With Metastatic Colorectal Cancer.. U.S. National Institutes of Health.
Ref 34 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800029052)
Ref 35 Clinical pipeline report, company report or official report of Genentech (2011).
Ref 36 Phase II Study of Saracatinib (AZD0530) in Patients With Previously Treated Metastatic Colorectal Cancer. Invest New Drugs. 2015 Aug;33(4):977-84.
Ref 37 Design and development of antisense drugs. Expert Opin. Drug Discov. 2008 3(10):1189-1207.